{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:28:49Z","timestamp":1789730929900,"version":"4.0.1"},"reference-count":202,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":57,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2023\/49\/N\/NZ5\/01525"],"award-info":[{"award-number":["2023\/49\/N\/NZ5\/01525"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.pharmthera.2025.108848","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T15:13:26Z","timestamp":1744038806000},"page":"108848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Investigation into biased signaling, glycosylation, and drug vulnerability of acute myeloid leukemia"],"prefix":"10.1016","volume":"270","author":[{"given":"Tomasz","family":"Pienkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Golonko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Bolkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Wawrzak-Pienkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Szczerbinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kretowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Ciborowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wlodzimierz","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Priebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Swislocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pharmthera.2025.108848_bb0005","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3324\/haematol.2019.240754","article-title":"Potential targeting of FLT3 acute myeloid leukemia","volume":"106","author":"Ambinder","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108848_bb0010","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/mend.11.5.9928","article-title":"Induction of promiscuous G protein coupling of the follicle-stimulating hormone (FSH) receptor: A novel mechanism for transducing pleiotropic actions of FSH isoforms","volume":"11","author":"Arey","year":"1997","journal-title":"Molecular Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.113.007724","article-title":"International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors","volume":"66","author":"Bachelerie","year":"2014","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0020","series-title":"Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy","first-page":"67","article-title":"FLT3 inhibitors as sensitizing agents for Cancer chemotherapy","author":"Baer","year":"2019"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.995124","article-title":"Editorial: Glucocorticoid and bone: Friend or foe","volume":"13","author":"Baschant","year":"2022","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0030","series-title":"Diagnostic Molecular Pathology: A Guide to Applied Molecular Testing","first-page":"419","article-title":"Molecular testing in acute myeloid leukemia","author":"Behdad","year":"2017"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108848_bb0035","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1073\/pnas.83.9.2797","article-title":"Beta-adrenergic receptor kinase: Identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor","volume":"83","author":"Benovic","year":"1986","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108848_bb0040","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1128\/jvi.70.9.6288-6295.1996","article-title":"A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains","volume":"70","author":"Berson","year":"1996","journal-title":"Journal of Virology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0045","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.celrep.2014.10.010","article-title":"Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor","volume":"9","author":"Bessman","year":"2014","journal-title":"Cell Reports"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108848_bb0050","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.3390\/cells10113058","article-title":"Integrated n-and o-glycomics of acute myeloid leukemia (Aml) cell lines","volume":"10","author":"Bl\u00f6chl","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0055","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-023-00981-0","article-title":"Transcriptionally imprinted glycomic signatures of acute myeloid leukemia","volume":"13","author":"Bl\u00f6chl","year":"2023","journal-title":"Cell & Bioscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0060","first-page":"1","article-title":"Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy","volume":"13","author":"Bolkun","year":"2023","journal-title":"Scientific Reports 2023 13:1"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0065","series-title":"Targeting the hedgehog and notch signaling pathways in Cancer stem cells","first-page":"103","author":"Borah","year":"2019"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108848_bb0070","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/ajh.25943","article-title":"Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed\/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients","volume":"95","author":"Borthakur","year":"2020","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1294555","article-title":"Ligand-based targeting of c-kit using engineered \u03b3\u03b4 T cells as a strategy for treating acute myeloid leukemia","volume":"14","author":"Branella","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0080","article-title":"Retinoid differentiation therapy for common types of acute myeloid leukemia","volume":"2012","author":"Brown","year":"2012","journal-title":"Leukemia Research and Treatment"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0085","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3390\/cancers15041030","article-title":"Cannabinoids transmogrify Cancer metabolic phenotype via epigenetic reprogramming and a novel CBD biased G protein-coupled receptor signaling platform","volume":"15","author":"Bunsick","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0090","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bbamem.2006.11.002","article-title":"Regulation of CXCR4 signaling","volume":"1768","author":"Busillo","year":"2007","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01672","article-title":"Targeting CXCR4 in AML and ALL","volume":"10","author":"Cancilla","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108848_bb0100","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.18632\/oncotarget.2233","article-title":"Cannabinoids as therapeutic agents in cancer: Current status and future implications","volume":"5","author":"Chakravarti","year":"2014","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108848_bb0105","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/acs.jproteome.6b00738","article-title":"Site-specific N-glycosylation of endothelial cell receptor tyrosine kinase VEGFR-2","volume":"16","author":"Chandler","year":"2017","journal-title":"Journal of Proteome Research"},{"issue":"5727","key":"10.1016\/j.pharmthera.2025.108848_bb0110","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1126\/science.1108595","article-title":"Allosteric mechanisms of signal transduction","volume":"308","author":"Changeux","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","article-title":"The intricate role of CXCR4 in cancer","volume":"124","author":"Chatterjee","year":"2014","journal-title":"Advances in Cancer Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108848_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052975","article-title":"All-trans-retinoic acid modulates ICAM-1 N-glycan composition by influencing GnT-III levels and inhibits cell adhesion and trans-endothelial migration","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.111893","article-title":"Arg kinase mediates CXCL12\/CXCR4-induced invadopodia formation and invasion of glioma cells","volume":"389","author":"Chen","year":"2020","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eng.2023.09.011","article-title":"The application of artificial intelligence accelerates G protein-coupled receptor ligand discovery","volume":"32","author":"Chen","year":"2024","journal-title":"Engineering"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108848_bb0155","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1128\/MCB.00556-06","article-title":"CXCR3 requires tyrosine Sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis","volume":"26","author":"Colvin","year":"2006","journal-title":"Molecular and Cellular Biology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108848_bb0160","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.tips.2017.05.010","article-title":"Applying structure-based drug design approaches to allosteric modulators of GPCRs","volume":"38","author":"Congreve","year":"2017","journal-title":"Trends in Pharmacological Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108848_bb0165","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood.V88.2.633.bloodjournal882633","article-title":"The novel anthracycline annamycin is not affected by P-glycoprotein- related multidrug resistance: Comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines","volume":"88","author":"Consoli","year":"1996","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108848_bb0170","doi-asserted-by":"crossref","first-page":"9542","DOI":"10.1074\/jbc.M114.596098","article-title":"Biased signaling at chemokine receptors","volume":"290","author":"Corbisier","year":"2015","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-024-01617-7","article-title":"Quizartinib: A potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD\u2013positive AML","volume":"17","author":"Cortes","year":"2024","journal-title":"Journal of Hematology and Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0180","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1124\/mol.59.4.707","article-title":"Human interferon-inducible 10-kDa protein and human interferon-inducible T cell \u03b1 chemoattractant are Allotopic ligands for human CXCR3: Differential binding to receptor states","volume":"59","author":"Cox","year":"2001","journal-title":"Molecular Pharmacology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2025.108848_bb0185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41417-019-0115-9","article-title":"Prognostic value of the FUT family in acute myeloid leukemia","volume":"27","author":"Dai","year":"2020","journal-title":"Cancer Gene Therapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108848_bb0190","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/leu.2011.62","article-title":"Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells","volume":"25","author":"Dar","year":"2011","journal-title":"Leukemia"},{"issue":"35","key":"10.1016\/j.pharmthera.2025.108848_bb0195","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus Gilteritinib for FLT3 -mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0200","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","article-title":"Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?","volume":"185","author":"Dempke","year":"2023","journal-title":"European journal of Cancer (Oxford, England\u00a0: 1990)"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"43","key":"10.1016\/j.pharmthera.2025.108848_bb0210","doi-asserted-by":"crossref","first-page":"17655","DOI":"10.1073\/pnas.1101133108","article-title":"Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways","volume":"108","author":"Drurya","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108848_bb0215","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1096\/fj.201902313RR","article-title":"Deficiency of core fucosylation activates cellular signaling dependent on FLT3 expression in a Ba\/F3 cell system","volume":"34","author":"Duan","year":"2020","journal-title":"FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.03018","article-title":"Potential role of CXCR4 targeting in the context of radiotherapy and immunotherapy of cancer","volume":"9","author":"Eckert","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109862","article-title":"Biased agonism at chemokine receptors","volume":"78","author":"Eiger","year":"2021","journal-title":"Cellular Signalling"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0230","first-page":"1","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nature Communications 2021 12:1"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0235","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0014-4827(02)00102-7","article-title":"Neuregulins: Functions, forms, and signaling strategies","volume":"284","author":"Falls","year":"2003","journal-title":"Experimental Cell Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108848_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111550","article-title":"Altered Protease\u2013Activated Receptor-1 Expression and Signaling in a Malignant Pleural Mesothelioma Cell Line, NCI-H28, with Homozygous Deletion of the \u03b2-Catenin Gene","volume":"9","author":"Fazzini","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108848_bb0245","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1046-5928(02)00569-7","article-title":"Expression of CB2 cannabinoid receptor in Pichia pastoris","volume":"26","author":"Feng","year":"2002","journal-title":"Protein Expression and Purification"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108848_bb0250","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2008-06-161539","article-title":"CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure","volume":"113","author":"Fiegl","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.carres.2023.108861","article-title":"D-glucose- and d-mannose-based antimetabolites. Part 4: Facile synthesis of mono- and di-acetates of 2-deoxy-d-glucose prodrugs as potentially useful antimetabolites","volume":"531","author":"Fokt","year":"2023","journal-title":"Carbohydrate Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108848_bb0260","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2017.09.017","article-title":"EGFR ligands differentially stabilize receptor dimers to specify signaling kinetics","volume":"171","author":"Freed","year":"2017","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108848_bb0265","first-page":"2132","article-title":"O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies","volume":"31","author":"Freund","year":"2017","journal-title":"Leukemia 2017 31:10"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0270","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","article-title":"Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations","volume":"232","author":"Gali\u00e8gue","year":"1995","journal-title":"European Journal of Biochemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108848_bb0275","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/2040620717721459","article-title":"Midostaurin: A novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis","volume":"8","author":"Gallogly","year":"2017","journal-title":"Therapeutic Advances in Hematology"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.996438","article-title":"Developments and challenges of FLT3 inhibitors in acute myeloid leukemia","volume":"12","author":"Ge","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.996438","article-title":"Developments and challenges of FLT3 inhibitors in acute myeloid leukemia","volume":"12","author":"Ge","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108848_bb0290","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.2019003124","article-title":"Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia","volume":"136","author":"Gebru","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0295","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.clml.2019.01.006","article-title":"Adding Oral pioglitazone to standard induction chemotherapy of acute myeloid leukemia: A randomized clinical Trial","volume":"19","author":"Ghadiany","year":"2019","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108848_bb0300","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.977358","article-title":"Explainable artificial intelligence for precision medicine in acute myeloid leukemia","volume":"13","author":"Gimeno","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108848_bb0310","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10120-018-0859-1","article-title":"E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function","volume":"22","author":"Godwin","year":"2019","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0315","first-page":"1","article-title":"Dietary factors and their influence on immunotherapy strategies in oncology: A comprehensive review","volume":"15","author":"Golonko","year":"2024","journal-title":"Cell Death & Disease 2024 15:4"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108848_bb0320","doi-asserted-by":"crossref","first-page":"342a","DOI":"10.1016\/j.bpj.2023.11.2076","article-title":"Allosteric restriction enhances sensitivity of the AML-associated Src-family kinase Fgr to ATP-site inhibitors","volume":"123","author":"Gonzalez-Areizaga","year":"2024","journal-title":"Biophysical Journal"},{"issue":"6599","key":"10.1016\/j.pharmthera.2025.108848_bb0325","first-page":"447","article-title":"\u0392-Arrestin acts as a clathrin adaptor in endocytosis of the \u03b22-adrenergic receptor","volume":"383","author":"Goodman","year":"1996","journal-title":"Nature 1996 383:6599"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108848_bb0330","first-page":"2589","article-title":"Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia","volume":"36","author":"Goyama","year":"2016","journal-title":"Oncogene 2017 36:18"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108848_bb0335","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3324\/haematol.2021.276048","article-title":"The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements","volume":"107","author":"Grasedieck","year":"2022","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108848_bb0340","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2009.26.0646","article-title":"High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities","volume":"28","author":"Gr\u00f6schel","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107540","article-title":"Biased GPCR signaling: Possible mechanisms and inherent limitations","volume":"211","author":"Gurevich","year":"2020","journal-title":"Pharmacology & Therapeutics"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108848_bb0350","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.bcp.2005.10.033","article-title":"The challenge of drug discovery of a GPCR target: Analysis of preclinical pharmacology of histamine H3 antagonists\/inverse agonists","volume":"71","author":"Hancock","year":"2006","journal-title":"Biochemical Pharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108848_bb0355","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: New agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nature Reviews Drug Discovery 2017 16:12"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108848_bb0360","first-page":"3976","article-title":"Targeting CXC motif chemokine receptor 4 inhibits the proliferation, migration and angiogenesis of lung cancer cells","volume":"16","author":"He","year":"2018","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0365","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.freeradbiomed.2017.04.018","article-title":"PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway","volume":"108","author":"Hocsak","year":"2017","journal-title":"Free Radical Biology and Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108848_bb0370","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.72.5.847","article-title":"Multiple control of interleukin-8 gene expression","volume":"72","author":"Hoffmann","year":"2002","journal-title":"Journal of Leukocyte Biology"},{"issue":"7396","key":"10.1016\/j.pharmthera.2025.108848_bb0375","first-page":"55","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","volume":"485","author":"Hsieh","year":"2012","journal-title":"Nature 2012 485:7396"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108848_bb0380","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-10-4162","article-title":"G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells","volume":"108","author":"Hyun","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1072028","article-title":"PCW-A1001, AI-assisted de novo design approach to design a selective inhibitor for FLT-3(D835Y) in acute myeloid leukemia","volume":"9","author":"Jang","year":"2022","journal-title":"Frontiers in Molecular Biosciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108848_bb0390","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/JLB.2MA0320-383RR","article-title":"Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors","volume":"107","author":"Jaracz-Ros","year":"2020","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2016.02.010","article-title":"Cannabinoid pharmacology in cancer research: A new hope for cancer patients?","volume":"775","author":"Javid","year":"2016","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0400","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders","volume":"8","author":"Jeffrey Conn","year":"2009","journal-title":"Nature Reviews Drug Discovery 2009 8:1"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108848_bb0405","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: From basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiological Reviews"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0410","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1158\/1535-7163.MCT-13-0858","article-title":"Preclinical evaluation of AMG 925, a FLT3\/CDK4 dual kinase inhibitor for treating acute myeloid leukemia","volume":"13","author":"Keegan","year":"2014","journal-title":"Molecular Cancer Therapeutics"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108848_bb0415","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1111\/bph.13217","article-title":"Gaddum memorial lecture 2014: Receptors as an evolving concept: From switches to biased microprocessors","volume":"172","author":"Kenakin","year":"2015","journal-title":"British Journal of Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108848_bb0420","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/j.1476-5381.2011.01749.x","article-title":"Biased signalling and allosteric machines: New vistas and challenges for drug discovery","volume":"165","author":"Kenakin","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108848_bb0425","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/mol.115.099192","article-title":"Biased Agonism and biased allosteric modulation at the CB1 cannabinoid receptor","volume":"88","author":"Khajehali","year":"2015","journal-title":"Molecular Pharmacology"},{"issue":"25","key":"10.1016\/j.pharmthera.2025.108848_bb0430","doi-asserted-by":"crossref","first-page":"21315","DOI":"10.18632\/oncotarget.4066","article-title":"CXCR1\/2 antagonism with CXCL8\/Interleukin-8 analogue CXCL8 (3-72) K11R\/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis","volume":"6","author":"Khan","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0435","first-page":"1","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nature Reviews Disease Primers 2016 2:1"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108848_bb0440","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108848_bb0445","doi-asserted-by":"crossref","first-page":"23214","DOI":"10.1074\/jbc.M402125200","article-title":"Differential desensitization, receptor phosphorylation, \u03b2-Arrestin recruitment, and ERK1\/2 activation by the two endogenous ligands for the CC chemokine receptor 7","volume":"279","author":"Kohout","year":"2004","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0450","first-page":"1","article-title":"IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia","volume":"5","author":"Kuett","year":"2015","journal-title":"Scientific Reports 2015 5:1"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108848_bb0455","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1158\/1535-7163.MCT-15-0163","article-title":"Antileukemic activity of 2-deoxy-D-glucose through inhibition of N-linked glycosylation in acute myeloid leukemia with FLT3-ITD or c-KIT mutations","volume":"14","author":"Larrue","year":"2015","journal-title":"Molecular Cancer Therapeutics"},{"issue":"26","key":"10.1016\/j.pharmthera.2025.108848_bb0460","doi-asserted-by":"crossref","first-page":"22880","DOI":"10.18632\/oncotarget.4412","article-title":"Co-expression of CXCL8 and HIF-1\u03b1 is associated with metastasis and poor prognosis in hepatocellular carcinoma","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108848_bb0465","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bbrc.2018.03.181","article-title":"CXCL8 is associated with the recurrence of patients with acute myeloid leukemia and cell proliferation in leukemia cell lines","volume":"499","author":"Li","year":"2018","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.695051","article-title":"Novel immune cell-based therapies to eradicate high-risk acute myeloid leukemia","volume":"12","author":"Limongello","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"20","key":"10.1016\/j.pharmthera.2025.108848_bb0475","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1158\/1078-0432.CCR-19-0510","article-title":"TRIB3 stabilizes high TWIST1 expression to promote rapid APL progression and ATRA resistance","volume":"25","author":"Lin","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0480","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1007\/s10753-018-0789-4","article-title":"\u03b24GalT1 mediates PPAR\u03b3 N-glycosylation to attenuate microglia inflammatory activation","volume":"41","author":"Liu","year":"2018","journal-title":"Inflammation"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108848_bb0485","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute Promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"4962","key":"10.1016\/j.pharmthera.2025.108848_bb0490","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1126\/science.2163110","article-title":"\u0392-Arrestin: A protein that regulates \u03b2-adrenergic receptor function","volume":"248","author":"Lohse","year":"1990","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108848_bb0495","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa025406","article-title":"Effect of priming with granulocyte Colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia","volume":"349","author":"L\u00f6wenberg","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118021","article-title":"TRIB3 destabilizes tumor suppressor PPAR\u03b1 expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia","volume":"257","author":"Luo","year":"2020","journal-title":"Life Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108848_bb0505","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/me.2013-1314","article-title":"Minireview: More than just a hammer: Ligand \u201cBias\u201d and pharmaceutical discovery","volume":"28","author":"Luttrell","year":"2014","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0510","series-title":"Automated Immunophenotyping assessment for diagnosing childhood acute leukemia using set-transformers","author":"Lygizou","year":"2024"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108848_bb0515","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.drudis.2020.07.004","article-title":"Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors","volume":"25","author":"Ma","year":"2020","journal-title":"Drug Discovery Today"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108848_bb0520","first-page":"e431","article-title":"Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: Identification of potential disease-specific targets","volume":"6","author":"Maiga","year":"2016","journal-title":"Blood Cancer Journal 2016 6:6"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115145","article-title":"Biased regulation of glucocorticoid receptors signaling","volume":"165","author":"Mao","year":"2023","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108848_bb0530","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005473","article-title":"Functional divergence in the role of N-linked glycosylation in smoothened signaling","volume":"11","author":"Marada","year":"2015","journal-title":"PLoS Genetics"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108848_bb0535","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108848_bb0540","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2014-11-611459","article-title":"Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells","volume":"125","author":"Martelli","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108848_bb0545","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3390\/cancers11121915","article-title":"Retinoic acid receptors in acute myeloid leukemia therapy","volume":"11","author":"di Martino","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111277","article-title":"Generalized and tissue specific glucocorticoid resistance","volume":"530","author":"Martins","year":"2021","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108848_bb0555","first-page":"1529","article-title":"Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions","volume":"130","author":"Medrano","year":"2024","journal-title":"British Journal of Cancer 2024 130:9"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-022-00849-9","article-title":"The activation of PPAR\u03b3 enhances Treg responses through up-regulating CD36\/CPT1-mediated fatty acid oxidation and subsequent N-glycan branching of T\u03b2RII\/IL-2R\u03b1","volume":"20","author":"Miao","year":"2022","journal-title":"Cell Communication and Signaling"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0565","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41389-024-00510-9","article-title":"Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy\/toxicity integration and bipartite network modeling","volume":"13","author":"Mirzaie","year":"2024","journal-title":"Oncogenesis"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108848_bb0570","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.3390\/cells10112967","article-title":"Transcriptome profiling of dysregulated GPCRs reveals overlapping patterns across psychiatric disorders and age-disease interactions","volume":"10","author":"Monfared","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108848_bb0575","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori","year":"2017","journal-title":"Investigational New Drugs"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108848_bb0580","first-page":"446","article-title":"Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy","volume":"29","author":"Mugoni","year":"2019","journal-title":"Cell Research 2019 29:6"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108848_bb0585","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2990.2010.01089.x","article-title":"Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity \u2013 A tale of conflict and conundrum","volume":"36","author":"M\u00fcller","year":"2010","journal-title":"Neuropathology and Applied Neurobiology"},{"issue":"6441","key":"10.1016\/j.pharmthera.2025.108848_bb0590","first-page":"61","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature 1993 365:6441"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108848_bb0595","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.tips.2020.02.001","article-title":"Combining allosteric and Orthosteric drugs to overcome drug resistance","volume":"41","author":"Ni","year":"2020","journal-title":"Trends in Pharmacological Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108848_bb0600","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/1535-7163.MCT-11-0915","article-title":"The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models","volume":"11","author":"Ning","year":"2012","journal-title":"Molecular Cancer Therapeutics"},{"issue":"185","key":"10.1016\/j.pharmthera.2025.108848_bb0605","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2001707","article-title":"Distinct phosphorylation sites on the \u03b2 2-adrenergic receptor establish a barcode that encodes differential functions of \u03b2-arrestin","volume":"4","author":"Nobles","year":"2011","journal-title":"Science Signaling"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108848_bb0610","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/j.clml.2021.09.002","article-title":"FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myeloid leukemia","volume":"22","author":"Novatcheva","year":"2022","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108848_bb0615","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119407","article-title":"Cannabinoid CB1 and CB2 receptors differentially regulate TNF-\u03b1-induced apoptosis and LPA1-mediated pro-survival signaling in HT22 hippocampal cells","volume":"276","author":"Olianas","year":"2021","journal-title":"Life Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108848_bb0625","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1101\/gad.1365406","article-title":"Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain","volume":"20","author":"Olsen","year":"2006","journal-title":"Genes & Development"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108848_bb0630","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.tips.2014.09.010","article-title":"What is biased efficacy? Defining the relationship between intrinsic efficacy and free energy coupling","volume":"35","author":"Onaran","year":"2014","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0635","doi-asserted-by":"crossref","unstructured":"Palena, C., Hamilton, D. H., & Fernando, R. I. (2012). Influence of IL-8 on The Epithelial\u2013Mesenchymal Transition and the Tumor Microenvironment. Future Oncology, 8(6), 713\u2013722. doi:https:\/\/doi.org\/10.2217\/FON.12.59.","DOI":"10.2217\/fon.12.59"},{"key":"10.1016\/j.pharmthera.2025.108848_bb1022","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1182\/blood-2023-184493","article-title":"Preliminary Results from a Phase 1\/2 Study of Liposomal Annamycin (L-ANN) in Combination with Cytarabin for the Treatment of Patients with Acute Myeloid Leukemia (AML) That Is Refractory to or Relapsed (r\/r) after Induction Therapy","volume":"142","author":"Papayannidis","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0640","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1124\/pharmrev.120.000082","article-title":"Post-translational modifications of G protein-coupled receptors control cellular signaling dynamics in space and time","volume":"73","author":"Patwardhan","year":"2021","journal-title":"Pharmacological Reviews"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108848_bb0645","first-page":"121","article-title":"Efficacy of all-trans-retinoic acid in high-risk acute myeloid leukemia with overexpression of EVI1","volume":"7","author":"Paubelle","year":"2019","journal-title":"Oncology and Therapy 2019 7:2"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108848_bb0650","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jnci\/djv077","article-title":"Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast Cancer","volume":"107","author":"P\u00e9rez-G\u00f3mez","year":"2015","journal-title":"JNCI Journal of the National Cancer Institute"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108848_bb0655","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1021\/jm400856t","article-title":"Polypharmacology - foe or friend?","volume":"56","author":"Peters","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmgm.2015.05.004","article-title":"Studying the binding interactions of allosteric agonists and antagonists of the CXCR4 receptor","volume":"60","author":"Planesas","year":"2015","journal-title":"Journal of Molecular Graphics and Modelling"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108848_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107684","article-title":"CXCR4 signaling has a CXCL12-independent essential role in murine MLL-AF9-driven acute myeloid leukemia","volume":"31","author":"Ramakrishnan","year":"2020","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117788","article-title":"Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges","volume":"182","author":"Rataj","year":"2025","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108848_bb0675","doi-asserted-by":"crossref","first-page":"830","DOI":"10.18632\/oncotarget.971","article-title":"Pharmacologic targeting of the PI3K\/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells","volume":"4","author":"Reikvam","year":"2013","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0680","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tem.2006.03.008","article-title":"GRKs and \u03b2-arrestins: Roles in receptor silencing, trafficking and signaling","volume":"17","author":"Reiter","year":"2006","journal-title":"Trends in Endocrinology and Metabolism"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108848_bb0685","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103277","article-title":"Cell signaling pathways as molecular targets to eliminate AML stem cells","volume":"160","author":"da Rodrigues","year":"2021","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108848_bb0695","first-page":"437","article-title":"Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells","volume":"29","author":"Saiki","year":"2006","journal-title":"International Journal of Oncology"},{"issue":"14","key":"10.1016\/j.pharmthera.2025.108848_bb0700","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108848_bb0705","doi-asserted-by":"crossref","first-page":"\\","DOI":"10.3390\/ijms20102417","article-title":"Influence of chemokine N-terminal modification on biased Agonism at the chemokine receptor CCR1","volume":"20","author":"Sanchez","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0710","first-page":"749","article-title":"Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors","volume":"28","author":"Sanchez","year":"2013","journal-title":"Leukemia 2014 28:4"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108848_bb0715","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/cncr.25868","article-title":"Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells","volume":"117","author":"Sandulache","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0720","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjh.13607","article-title":"Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide","volume":"171","author":"Sanford","year":"2015","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0725","doi-asserted-by":"crossref","first-page":"1415618","DOI":"10.3389\/frhem.2024.1415618","article-title":"The SWEET symphony of n-GLYCANS in myeloid malignancies","volume":"3","author":"Sanmart\u00edn Mart\u00ednez","year":"2024","journal-title":"Frontiers in Hematology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108848_bb0730","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2174\/1389203724666230822100131","article-title":"BH3 mimetic peptides: An effective strategy to complement anticancer therapy","volume":"24","author":"Saraswathy","year":"2023","journal-title":"Current Protein & Peptide Science"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2025.108848_bb0735","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bbrc.2015.10.116","article-title":"C-Mannosylation of thrombopoietin receptor (c-Mpl) regulates thrombopoietin-dependent JAK-STAT signaling","volume":"468","author":"Sasazawa","year":"2015","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0740","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0745","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","article-title":"Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor","volume":"32","author":"Schattauer","year":"2017","journal-title":"Cellular Signalling"},{"issue":"20","key":"10.1016\/j.pharmthera.2025.108848_bb0750","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1182\/blood-2015-01-621631","article-title":"IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells","volume":"125","author":"Schinke","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0755","first-page":"339","article-title":"Structural diversity of G protein-coupled receptors and significance for drug discovery","volume":"7","author":"Schi\u00f6th","year":"2008","journal-title":"Nature Reviews Drug Discovery 2008 7:4"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108848_bb0760","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1182\/blood-2004-01-0272","article-title":"G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow","volume":"106","author":"Semerad","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0765","first-page":"1","article-title":"Lost in translation: The valley of death across preclinical and clinical divide \u2013 Identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Translational Medicine Communications 2019 4:1"},{"issue":"49","key":"10.1016\/j.pharmthera.2025.108848_bb0770","doi-asserted-by":"crossref","first-page":"35093","DOI":"10.1074\/jbc.M113.511949","article-title":"Negative regulation of interferon-induced transmembrane protein 3 by SET7-mediated lysine Monomethylation","volume":"288","author":"Shan","year":"2013","journal-title":"Journal of Biological Chemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108848_bb0775","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.tips.2011.05.002","article-title":"\u0392-Arrestin-mediated receptor trafficking and signal transduction","volume":"32","author":"Shenoy","year":"2011","journal-title":"Trends in Pharmacological Sciences"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108848_bb0780","first-page":"1802","article-title":"Exosomal circSPIRE1 mediates glycosylation of E-cadherin to suppress metastasis of renal cell carcinoma","volume":"42","author":"Shu","year":"2023","journal-title":"Oncogene 2023 42:22"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108848_bb0785","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.cell.2020.04.053","article-title":"\u0392-Arrestin-biased allosteric modulator of NTSR1 selectively attenuates addictive behaviors","volume":"181","author":"Slosky","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0790","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.tips.2020.12.005","article-title":"Biased allosteric modulators: New Frontiers in GPCR drug discovery","volume":"42","author":"Slosky","year":"2021","journal-title":"Trends in Pharmacological Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0795","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrd.2017.229","article-title":"Biased signalling: From simple switches to allosteric microprocessors","volume":"17","author":"Smith","year":"2018","journal-title":"Nature Reviews Drug Discovery 2018 17:4"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108848_bb0800","doi-asserted-by":"crossref","first-page":"8969","DOI":"10.1074\/jbc.R115.713313","article-title":"The \u03b2-Arrestins: Multifunctional regulators of G protein-coupled receptors","volume":"291","author":"Smith","year":"2016","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0805","first-page":"1","article-title":"Identification of global inhibitors of cellular glycosylation","volume":"14","author":"S\u00f8rensen","year":"2023","journal-title":"Nature Communications 2023 14:1"},{"issue":"27","key":"10.1016\/j.pharmthera.2025.108848_bb0810","first-page":"E3600","article-title":"N-linked glycosylation of protease-activated receptor-1 at extracellular loop 2 regulates G-protein signaling bias","volume":"112","author":"Soto","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"24","key":"10.1016\/j.pharmthera.2025.108848_bb0815","doi-asserted-by":"crossref","first-page":"18781","DOI":"10.1074\/jbc.M110.111088","article-title":"N-linked glycosylation of protease-activated Receptor-1 second extracellular loop: A critical determinant for ligand-induced receptor activation and internalization","volume":"285","author":"Soto","year":"2010","journal-title":"Journal of Biological Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108848_bb0820","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tibs.2020.02.006","article-title":"Gene-specific actions of transcriptional Coregulators facilitate physiological plasticity: Evidence for a physiological Coregulator code","volume":"45","author":"Stallcup","year":"2020","journal-title":"Trends in Biochemical Sciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108848_bb0825","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108848_bb0830","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3324\/haematol.2022.282316","article-title":"Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience","volume":"108","author":"Sun","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0835","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00155","article-title":"Fatty acid metabolism, bone marrow adipocytes, and AML","volume":"10","author":"Tabe","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108848_bb0840","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108848_bb0845","article-title":"CAR\u2019TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment","volume":"32","author":"Teppert","year":"2024","journal-title":"Molecular Therapy: Oncology"},{"issue":"14","key":"10.1016\/j.pharmthera.2025.108848_bb0850","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1111\/bph.16099","article-title":"Targeting G protein-coupled receptors for heart failure treatment","volume":"181","author":"Thai","year":"2024","journal-title":"British Journal of Pharmacology"},{"issue":"JULY","key":"10.1016\/j.pharmthera.2025.108848_bb0855","article-title":"A general introduction to glucocorticoid biology","volume":"10","author":"Timmermans","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108848_bb0860","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood.V82.8.2517.2517","article-title":"Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia","volume":"82","author":"Tobler","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0865","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ceb.2020.01.016","article-title":"Receptor tyrosine kinase activation: From the ligand perspective","volume":"63","author":"Trenker","year":"2020","journal-title":"Current Opinion in Cell Biology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108848_bb0870","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1046\/j.1365-2443.1998.00223.x","article-title":"Role of Bcl-2 family proteins in apoptosis: Apoptosomes or mitochondria?","volume":"3","author":"Tsujimoto","year":"1998","journal-title":"Genes to Cells"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108848_bb0875","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5152\/balkanmedj.2014.13103","article-title":"The endocannabinoid system as a potential therapeutic target for pain modulation","volume":"31","author":"Ulug\u00f6l","year":"2014","journal-title":"Balkan Medical Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0880","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.3390\/ijms24043727","article-title":"The Immuno-oncology and genomic aspects of DNA-Hypomethylating therapeutics in acute myeloid leukemia","volume":"24","author":"Urabe","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108848_bb0885","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108848_bb0890","first-page":"874","article-title":"Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells","volume":"111","author":"Valenzuela","year":"2014","journal-title":"British Journal of Cancer 2014 111:5"},{"issue":"s1","key":"10.1016\/j.pharmthera.2025.108848_bb0895","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3747\/co.23.3080","article-title":"Anticancer mechanisms of cannabinoids","volume":"23","author":"Velasco","year":"2016","journal-title":"Current Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108848_bb0900","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2015-07-653840","article-title":"Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid","volume":"127","author":"Verhagen","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108848_bb0905","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tips.2014.04.007","article-title":"Biased ligands at G-protein-coupled receptors: Promise and progress","volume":"35","author":"Violin","year":"2014","journal-title":"Trends in Pharmacological Sciences"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108848_bb0910","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.2174\/0929867325666180117105522","article-title":"The role of AMPK\/mTOR modulators in the therapy of acute myeloid leukemia","volume":"26","author":"Visnjic","year":"2018","journal-title":"Current Medicinal Chemistry"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108848_bb0915","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1084\/jem.20150452","article-title":"Hif-1\u03b1 and Hif-2\u03b1 synergize to suppress AML development but are dispensable for disease maintenance","volume":"212","author":"Vukovic","year":"2015","journal-title":"Journal of Experimental Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0920","first-page":"1","article-title":"N-glycosylation can selectively block or foster different receptor\u2013ligand binding modes","volume":"11","author":"Vuorio","year":"2021","journal-title":"Scientific Reports 2021 11:1"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108848_bb0925","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"The Lancet. Oncology"},{"issue":"19","key":"10.1016\/j.pharmthera.2025.108848_bb0930","doi-asserted-by":"crossref","first-page":"10782","DOI":"10.1073\/pnas.1834556100","article-title":"Independent \u03b2-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2","volume":"100","author":"Wei","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108848_bb0935","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1111\/jcmm.14927","article-title":"Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia","volume":"24","author":"Weisberg","year":"2020","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108848_bb0940","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2010-08-300087","article-title":"Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice","volume":"117","author":"Welch","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108848_bb0945","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molmed.2010.11.004","article-title":"Therapeutic potential of \u03b2-arrestin- and G protein-biased agonists","volume":"17","author":"Whalen","year":"2011","journal-title":"Trends in Molecular Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0950","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2008.11.008","article-title":"Functional selectivity of EGF family peptide growth factors: Implications for cancer","volume":"122","author":"Wilson","year":"2009","journal-title":"Pharmacology & Therapeutics"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108848_bb0955","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41580-018-0049-3","article-title":"Mechanisms of signalling and biased agonism in G protein-coupled receptors","volume":"19","author":"Wootten","year":"2018","journal-title":"Nature Reviews Molecular Cell Biology 2018 19:10"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb0960","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-018-1539-y","article-title":"Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia","volume":"16","author":"Wu","year":"2018","journal-title":"Journal of Translational Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108848_bb0965","first-page":"1","article-title":"Bcl-2 inhibition combined with PPAR\u03b1 activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia","volume":"14","author":"Xie","year":"2023","journal-title":"Cell Death & Disease 2023 14:8"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0970","first-page":"4953","article-title":"CXCR4 in breast cancer: Oncogenic role and therapeutic targeting","volume":"9","author":"Xu","year":"2015","journal-title":"Drug Design, Development and Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108848_bb0975","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7150\/ijms.33532","article-title":"Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death","volume":"16","author":"Xu","year":"2019","journal-title":"International Journal of Medical Sciences"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0980","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.trsl.2019.05.004","article-title":"Characterization of upregulated adhesion GPCRs in acute myeloid leukemia","volume":"212","author":"Yang","year":"2019","journal-title":"Translational Research"},{"key":"10.1016\/j.pharmthera.2025.108848_bb0985","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01787","article-title":"Decitabine-mediated epigenetic reprograming enhances anti-leukemia efficacy of CD123-targeted chimeric antigen receptor T-cells","volume":"11","author":"You","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2025.108848_bb0990","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-139752","volume":"136","author":"Zeidan","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108848_bb0995","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.clml.2022.01.012","article-title":"A phase 1\/2 study of the Oral Janus kinase 1 inhibitors INCB052793 and Itacitinib alone or in combination with standard therapies for advanced hematologic malignancies","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"24","key":"10.1016\/j.pharmthera.2025.108848_bb1000","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","article-title":"Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML","volume":"113","author":"Zeng","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108848_bb1005","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1182\/blood-2011-11-393934","article-title":"Targeting of mTORC1\/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment","volume":"120","author":"Zeng","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108848_bb1010","first-page":"1","article-title":"G protein-coupled receptors (GPCRs): Advances in structures, mechanisms and drug discovery","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduction and Targeted Therapy 2024 9:1"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108848_bb1015","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/cbin.11246","article-title":"HIF-1\u03b1 forms regulatory loop with YAP to coordinate hypoxia-induced adriamycin resistance in acute myeloid leukemia cells","volume":"44","author":"Zhu","year":"2020","journal-title":"Cell Biology International"},{"key":"10.1016\/j.pharmthera.2025.108848_bib1021","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1182\/blood-2019-131977","article-title":"Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model","volume":"134","author":"Zielinski","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108848_bb1020","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1172\/JCI71951","article-title":"CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis","volume":"124","author":"Zohar","year":"2014","journal-title":"The Journal of Clinical Investigation"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825000609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825000609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T13:44:42Z","timestamp":1753796682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725825000609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":202,"alternative-id":["S0163725825000609"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108848","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation into biased signaling, glycosylation, and drug vulnerability of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108848"}}